<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37730483</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2152-2669</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Clinical lymphoma, myeloma &amp; leukemia</Title><ISOAbbreviation>Clin Lymphoma Myeloma Leuk</ISOAbbreviation></Journal><ArticleTitle>Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2152-2650(23)00276-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clml.2023.08.016</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early mortality is a historical measure of the quality of care incorporated into many quality measure algorithms that mostly account for patient comorbidities but do not incorporate disease characteristics and treatment status which independently increase early mortality. This is particularly significant in leukemia, especially in the refractory and salvage settings.</AbstractText><AbstractText Label="STUDY AIM" NlmCategory="OBJECTIVE">To define the independent adverse effect of leukemia salvage vs. frontline therapy on early mortality in acute myeloid leukemia (AML) after accounting for the pretreatment independent adverse effects associated with early mortality.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A total of 4151 patients with AML were analyzed, 2893 newly diagnosed and 1258 in salvage. Univariate and multivariate analyses (MVA) were conducted to determine the independent adverse effects associated with 8-week mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 8-week mortality was 13% in frontline therapy and 18% in salvage therapy. By MVA, older age; therapy-related AML; prior history of myelodysplastic syndrome; poorer performance status; high white blood cell count; lower platelet count; higher percent of peripheral blasts; lower albumin levels; higher bilirubin, creatinine, and lactate dehydrogenase levels; and adverse cytogenetic risk groups were independently associated with a higher 8-week mortality rate. Adding treatment status after accounting for the independent adverse variables still selected salvage status as significantly adverse for 8-week mortality (hazard ratio 1.954; P-value &lt; .001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Quality measure algorithms should incorporate a risk mortality index related to leukemia vs. other tumors and benign conditions and a risk mortality index related to the treatment status of leukemia (salvage vs. frontline therapy).</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravandi</LastName><ForeName>Farhad</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiNardo</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welch</LastName><ForeName>Mary Alma</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadia</LastName><ForeName>Tapan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarjian</LastName><ForeName>Hagop</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: hkantarjian@mdanderson.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Lymphoma Myeloma Leuk</MedlineTA><NlmUniqueID>101525386</NlmUniqueID><ISSNLinking>2152-2669</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">8-week mortality</Keyword><Keyword MajorTopicYN="N">Chemotherapy at the end of life</Keyword><Keyword MajorTopicYN="N">Early mortality after chemotherapy in leukemia</Keyword><Keyword MajorTopicYN="N">Induction mortality</Keyword></KeywordList><CoiStatement>Disclosures The authors have stated that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>20</Day><Hour>21</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37730483</ArticleId><ArticleId IdType="doi">10.1016/j.clml.2023.08.016</ArticleId><ArticleId IdType="pii">S2152-2650(23)00276-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>